Ignite Creation Date:
2024-05-06 @ 7:06 PM
Last Modification Date:
2025-12-17 @ 7:03 PM
Study NCT ID:
NCT05891275
Status:
None
Last Update Posted:
2025-05-01 00:00:00
First Post:
2023-05-26 00:00:00
Brief Title:
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Characterization of Patients With Geographic Atrophy (GA) in the US
Status:
None
Status Verified Date:
2025-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None